Bierle DM, Ganesh R, Tulledge-Scheitel S, et al. - Fully vaccinated individuals may experience breakthrough COVID-19 especially during the SARS-CoV-2 Delta surge. Researchers herein examined the rates of severe disease in fully vaccinated patients with breakthrough COVID-19, as measured by oxygen requirement and need for hospitalization. Further, they compared these outcomes between patients who received or did not receive treatment with anti-spike monoclonal antibody.

• A cohort study of 1,395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID-19.

• Hospitalization was required in 107 (7.7%) persons by day 28.

• The number of medical comorbidities significantly associated with hospitalization.

• A lower risk of hospitalization was observed in significant correlation with receiving anti-spike monoclonal antibody treatment.

• To prevent one hospitalization, the number needed to treat (NNT) was 225 vs 4 among the lowest-risk patient group vs those with highest numbers of medical comorbidity, respectively.